Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 3Other hematologic neoplasm 1

Conditions

Breast Neoplasms 3Cardiotoxicity 2Hematologic Neoplasms 1Heart Failure 1Cardiomyopathies 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × Carvedilol × Clear all
NCT04023110 2025-10-09

CCTGuide Pilot

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
68 enrolled 20 charts
Breast

Breast Neoplasms, Heart Failure, Cardiomyopathies, Cardiotoxicity

NCT02717507 2025-04-23

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

Children's Oncology Group

Phase 2 Completed
196 enrolled 26 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT02177175 2022-07-12

Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
82 enrolled 13 charts
Breast

Breast Neoplasms

NCT01009918 2021-03-30

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

University of South Florida

Phase 2 Completed
468 enrolled 16 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡